Learn More About Pre-Exposure Prophylaxis (PrEP) Funding Opportunities

Vaccine Innovation & Therapeutics
Accelerator Launchpad (VITAL)

Accelerating the Next Generation of Therapeutics Platforms and Technologies

VITAL is an accelerator hub in the U.S. Biomedical Advanced Research and Development Authority (BARDA) Accelerator Network (BAN). The BAN fosters growth of the global health security innovation ecosystem by supporting early-stage companies to overcome their business, marketing, and operational hurdles. VITAL supports development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security, and is managed by Start2 Group, with partners Advise Connect Inspire (ACI) and BioLabs.

VITAL's Services

Annual Accelerator

VITAL supports health security innovators, startups, and portfolio companies by providing de-risking and accelerator services including entrepreneurship education and access to technical and business experts and resources.

Non-Dilutive Funding

VITAL provides non-dilutive funding to startups and academic innovators for the development, evaluation, and validation of innovative therapeutics solutions that align with BARDA’s strategic priorities.

Non-Dilutive Funding to Advance Your Therapeutic Innovations

Are you working on groundbreaking therapeutics solutions? The VITAL Hub seeks proposals for the development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security. Multi-use/platform technologies are preferred for this solicitation. VITAL invites startups and university-backed projects to apply for non-dilutive funding from $50K to $200K.

The VITAL Accelerator Program

Are you a startup or university-based project pioneering the future of therapeutics and vaccines? We’re looking for innovative solutions that align with BARDA’s mission to enhance pandemic preparedness and health security. Apply to the VITAL Accelerator Program and make a global impact! 

Non-Dilutive Funding to Advance Platform Approaches for Pre-Exposure Prophylaxis (PrEP)

Now Accepting Applications!

VITAL and BARDA are seeking innovations to improve delivery, biodistribution, and durability of long-acting monoclonal antibody and/or nucleic acid-based platforms for PrEP for seasonal and pandemic influenza and other respiratory viruses.

VITAL Insights On-Demand:
Watch Our Webinar Info Session

Watch our info session to gain insights into the VITAL Biotech Accelerator Program and Funding opportunities.

Mark Your Calendar!

BARDA VITAL Hub Symposium

June 27, 2024 at 2 PM CET | Berlin, Germany

Join us at the BARDA VITAL Hub Symposium in Berlin for cutting-edge insights on advancements in pandemic preparedness to combat infectious diseases and enhance global health security. Connect with global experts from the U.S., Canada, and EU to explore the latest discoveries and strategies in preventing and addressing global health crises.

Established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), the BARDA Accelerator Network (BAN) fosters the growth of health security innovation ecosystems globally and accelerates the development and commercialization of next-generation health security solutions.

BARDA Accelerator Network Hubs